Hb zoeterwoude [beta23(B5)Val-->Ala)]: a new beta-globin variant found in association with erythrocytosis. 2005

Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
The Hemoglobinopathies Laboratory, Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. c.l.harteveld@lumc.nl

We describe the characterization of a new hemoglobin (Hb) variant found in a 77-year-old Dutch woman, suspected of hypoxia-mediated erythrocytosis. The typical blood parameters (Hb 17.3 g/dL; PCV 0.525 L/L; RBC 5.82 x 10(12)/L) could not be explained by any of the pathological or physiological conditions causing erythrocytosis. The patient was preventively phlebotomized because of intermittent claudication and erythrocytosis. At the hematological and biochemical levels, no anemia or hemolysis were present and no abnormal Hb fractions were detectable on alkaline electrophoresis or high performance liquid chromatography (HPLC). Molecular analysis revealed intact alpha-globin genes and a heterozygosity for a GTT-->GCT transition at codon 23 of the beta-globin gene, causing a Val-->Ala amino acid substitution. The P50 measured in full blood indicated that this mutant has an elevated oxygen affinity. This is the fourth single nucleotide substitution at codon 23 of the beta gene and the second associated with erythrocytosis. Because the family was not available for investigation no information was obtained as to whether the mutation represents a de novo event or was inherited, and might be a more common cause of erythrocytosis in Dutch patients. Considering the relatively high frequency of beta-thalassemia (thal) in the large allochthonous population in The Netherlands, combinations of Hb Zoeterwoude and beta-thal traits may lead to hemizygosity, with severe hypoxia and erythrocytosis from a few months after birth.

UI MeSH Term Description Entries
D011086 Polycythemia An increase in the total red cell mass of the blood. (Dorland, 27th ed) Erythrocytosis,Erythrocytoses,Polycythemias
D003062 Codon A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE). Codon, Sense,Sense Codon,Codons,Codons, Sense,Sense Codons
D005260 Female Females
D006455 Hemoglobins, Abnormal Hemoglobins characterized by structural alterations within the molecule. The alteration can be either absence, addition or substitution of one or more amino acids in the globin part of the molecule at selected positions in the polypeptide chains. Abnormal Hemoglobins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000860 Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms. Anoxia,Oxygen Deficiency,Anoxemia,Deficiency, Oxygen,Hypoxemia,Deficiencies, Oxygen,Oxygen Deficiencies
D017354 Point Mutation A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair. Mutation, Point,Mutations, Point,Point Mutations
D019943 Amino Acid Substitution The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties. Amino Acid Substitutions,Substitution, Amino Acid,Substitutions, Amino Acid

Related Publications

Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
February 2001, Hemoglobin,
Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
January 1990, Hemoglobin,
Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
January 2008, Hemoglobin,
Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
March 2010, Biochimica et biophysica acta,
Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
July 1994, European journal of haematology,
Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
January 1991, Hemoglobin,
Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
January 1991, Hemoglobin,
Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
July 1999, American journal of hematology,
Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
January 2005, Hemoglobin,
Cornelis L Harteveld, and J H Marc Groeneveld, and Bastiaan van Dam, and Peter Van Delft, and Nicole Akkerman, and Sandra Arkesteijn, and Piero C Giordano
May 2002, Hemoglobin,
Copied contents to your clipboard!